Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

Similar articles for PubMed (Select 21068778)

1.

Allogeneic gene-modified tumor cells (RCC-26/IL-7/CD80) as a vaccine in patients with metastatic renal cell cancer: a clinical phase-I study.

Westermann J, Flörcken A, Willimsky G, van Lessen A, Kopp J, Takvorian A, Jöhrens K, Lukowsky A, Schönemann C, Sawitzki B, Pohla H, Frank R, Dörken B, Schendel DJ, Blankenstein T, Pezzutto A.

Gene Ther. 2011 Apr;18(4):354-63. doi: 10.1038/gt.2010.143. Epub 2010 Nov 11.

PMID:
21068778
2.

Phase 1 trial of allogeneic gene-modified tumor cell vaccine RCC-26/CD80/IL-2 in patients with metastatic renal cell carcinoma.

Buchner A, Pohla H, Willimsky G, Frankenberger B, Frank R, Baur-Melnyk A, Siebels M, Stief CG, Hofstetter A, Kopp J, Pezzutto A, Blankenstein T, Oberneder R, Schendel DJ.

Hum Gene Ther. 2010 Mar;21(3):285-97. doi: 10.1089/hum.2008.192.

PMID:
19788391
3.

Influence of CD80, interleukin-2, and interleukin-7 expression in human renal cell carcinoma on the expansion, function, and survival of tumor-specific CTLs.

Frankenberger B, Pohla H, Noessner E, Willimsky G, Papier B, Pezzutto A, Kopp J, Oberneder R, Blankenstein T, Schendel DJ.

Clin Cancer Res. 2005 Mar 1;11(5):1733-42.

4.

Patient-derived renal cell carcinoma cells fused with allogeneic dendritic cells elicit anti-tumor activity: in vitro results and clinical responses.

Zhou J, Weng D, Zhou F, Pan K, Song H, Wang Q, Wang H, Wang H, Li Y, Huang L, Zhang H, Huang W, Xia J.

Cancer Immunol Immunother. 2009 Oct;58(10):1587-97. doi: 10.1007/s00262-009-0668-9. Epub 2009 Feb 17.

PMID:
19221746
5.

Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma.

Avigan DE, Vasir B, George DJ, Oh WK, Atkins MB, McDermott DF, Kantoff PW, Figlin RA, Vasconcelles MJ, Xu Y, Kufe D, Bukowski RM.

J Immunother. 2007 Oct;30(7):749-61.

PMID:
17893567
6.

Phase I trial of a B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma.

Antonia SJ, Seigne J, Diaz J, Muro-Cacho C, Extermann M, Farmelo MJ, Friberg M, Alsarraj M, Mahany JJ, Pow-Sang J, Cantor A, Janssen W.

J Urol. 2002 May;167(5):1995-2000.

PMID:
11956426
7.

Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma.

Kaufman HL, Taback B, Sherman W, Kim DW, Shingler WH, Moroziewicz D, DeRaffele G, Mitcham J, Carroll MW, Harrop R, Naylor S, Kim-Schulze S.

J Transl Med. 2009 Jan 7;7:2. doi: 10.1186/1479-5876-7-2.

8.

Adoptive cellular therapy with tumor vaccine draining lymph node lymphocytes after vaccination with HLA-B7/beta2-microglobulin gene-modified autologous tumor cells.

Meijer SL, Dols A, Urba WJ, Hu HM, Smith II JW, Vetto J, Wood W, Doran T, Chu Y, Sayaharuban P, Alvord WG, Fox BA.

J Immunother. 2002 Jul-Aug;25(4):359-72.

PMID:
12142559
9.

Allogeneic partially HLA-matched dendritic cells pulsed with autologous tumor cell lysate as a vaccine in metastatic renal cell cancer: a clinical phase I/II study.

Flörcken A, Kopp J, van Lessen A, Movassaghi K, Takvorian A, Jöhrens K, Möbs M, Schönemann C, Sawitzki B, Egerer K, Dörken B, Pezzutto A, Westermann J.

Hum Vaccin Immunother. 2013 Jun;9(6):1217-27. doi: 10.4161/hv.24149. Epub 2013 Mar 4.

10.

A CD80-transfected human breast cancer cell variant induces HER-2/neu-specific T cells in HLA-A*02-matched situations in vitro as well as in vivo.

Gückel B, Stumm S, Rentzsch C, Marmé A, Mannhardt G, Wallwiener D.

Cancer Immunol Immunother. 2005 Feb;54(2):129-40. Epub 2004 Sep 9.

PMID:
15365776
11.

Tumor cell-based vaccination in renal cell carcinoma: rationale. approaches, and recent clinical development.

Volk J, Sel S, Ganser A, Schöffski P.

Curr Drug Targets. 2002 Oct;3(5):401-8. Review.

PMID:
12182231
12.

Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a phase 1 study.

Oosterwijk-Wakka JC, Tiemessen DM, Bleumer I, de Vries IJ, Jongmans W, Adema GJ, Debruyne FM, de Mulder PH, Oosterwijk E, Mulders PF.

J Immunother. 2002 Nov-Dec;25(6):500-8.

PMID:
12439347
13.

Vaccination of women with metastatic breast cancer, using a costimulatory gene (CD80)-modified, HLA-A2-matched, allogeneic, breast cancer cell line: clinical and immunological results.

Dols A, Smith JW 2nd, Meijer SL, Fox BA, Hu HM, Walker E, Rosenheim S, Moudgil T, Doran T, Wood W, Seligman M, Alvord WG, Schoof D, Urba WJ.

Hum Gene Ther. 2003 Jul 20;14(11):1117-23.

PMID:
12885350
15.

Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma: a clinical phase 1/2 trial.

Berntsen A, Trepiakas R, Wenandy L, Geertsen PF, thor Straten P, Andersen MH, Pedersen AE, Claesson MH, Lorentzen T, Johansen JS, Svane IM.

J Immunother. 2008 Oct;31(8):771-80. doi: 10.1097/CJI.0b013e3181833818.

PMID:
18779742
16.

Therapeutic vaccination against metastatic carcinoma by expression-modulated and immunomodified autologous tumor cells: a first clinical phase I/II trial.

Wittig B, Märten A, Dorbic T, Weineck S, Min H, Niemitz S, Trojaneck B, Flieger D, Kruopis S, Albers A, Löffel J, Neubauer A, Albers P, Müller S, Sauerbruch T, Bieber T, Huhn D, Schmidt-Wolf IG.

Hum Gene Ther. 2001 Feb 10;12(3):267-78.

PMID:
11177563
17.

[Efficacy of autologous renal tumor cell lysate-loaded dendritic cell vaccine in combination with cytokine-induced killer cells on advanced renal cell carcinoma--a report of ten cases].

Wang H, Zhou FJ, Wang QJ, Qin ZK, Huang LX, Liu ZW, Han H, Li YQ, Chen SP, Xia JC.

Ai Zheng. 2006 May;25(5):625-30. Chinese.

PMID:
16687087
18.

A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings.

Oudard S, Rixe O, Beuselinck B, Linassier C, Banu E, Machiels JP, Baudard M, Ringeisen F, Velu T, Lefrere-Belda MA, Limacher JM, Fridman WH, Azizi M, Acres B, Tartour E.

Cancer Immunol Immunother. 2011 Feb;60(2):261-71. doi: 10.1007/s00262-010-0935-9. Epub 2010 Nov 11.

PMID:
21069322
19.

B7-1 gene-modified autologous tumor-cell vaccines for renal-cell carcinoma.

Antonia SJ, Seigne JD.

World J Urol. 2000 Apr;18(2):157-63. Review.

PMID:
10854153
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk